Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology.
Marc P Bonaca, Benjamin A Olenchock, Joe-Elie Salem...
https://pubmed.ncbi.nlm.nih.gov/31390169/Actively Recruiting
Led by Groupe Hospitalier Pitie-Salpetriere · Updated on 2026-09-11
500000
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating cardiovascular toxicities that may result from immune checkpoint inhibitors ICIs, which are drugs used to treat various cancers. This study focuses on identifying risk factors for these heart-related side effects by analyzing data from international and French health databases, including the World Health Organization WHO database VigiBase, the Assistance Publique Hopitaux de Paris Entrepot de Donne9es de Sante9 APHP.EDS, the French Syste8me National Des Donne9es de Sante9 SNDS Databases, and a retrospective international multicenter registry of ICI-associated myocarditis. The goal is to better understand the occurrence and causes of these adverse events in patients receiving ICIs. The study evaluates reports of cardiovascular adverse reactions linked to ICIs targeting PD-1, PD-L1, or CTLA-4, including drugs such as Ipilimumab, Nivolumab, Pembrolizumab, Durvalumab, Avelumab, Atezolizumab, and Cemiplimab. Data is collected from cases documented in the mentioned databases up to January 2025. The analysis includes comparison of cases with cardiovascular toxicity to patients exposed to ICIs without such events. Participants do not undergo active treatment as this is an observational study analyzing existing safety reports. The research team examines various cardiovascular conditions and adverse events using detailed medical terms and classifications. They assess factors such as drug interactions, treatment duration, types of cardiotoxicity, and patient characteristics. The primary outcome is identifying risk factors for cardiovascular toxicity attributed to ICIs. The study includes extensive data review and monitoring until January 2030 to gather comprehensive information.
CONDITIONS
JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors
J
Joe-Elie SALEM, MD PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Groupe Hospitalier Pitie-Salpetriere
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - From study start in 2019 until 2030
Researchers review reports of cardiovascular adverse events related to immune checkpoint inhibitors from international and French health databases and registries.
No participant visits required
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Marc P Bonaca, Benjamin A Olenchock, Joe-Elie Salem...
https://pubmed.ncbi.nlm.nih.gov/31390169/Joe-Elie Salem, Yves Allenbach, Aurore Vozy...
https://pubmed.ncbi.nlm.nih.gov/31189043/Lee S Nguyen, Marie Bretagne, Jennifer Arrondeau...
https://pubmed.ncbi.nlm.nih.gov/35383117/Joe-Elie Salem, Ali Manouchehri, Melissa Moey...
https://pubmed.ncbi.nlm.nih.gov/30442497/John R Power, Charles Dolladille, Benay Ozbay...
https://pubmed.ncbi.nlm.nih.gov/40569849/Javid J Moslehi, Joe-Elie Salem, Jeffrey A Sosman...
https://pubmed.ncbi.nlm.nih.gov/29536852/John R Power, Charles Dolladille, Benay Ozbay...
https://pubmed.ncbi.nlm.nih.gov/38883792/Groupe Hospitalier Pitie-Salpetriere
Lead Sponsor